Risks and benefits of phase 1 clinical trials for patients with relapsed or refractory lymphoma, from 2008 to 2023.

Trials including drug further approved by health authorities involved 84/447 (18.8%) of patients and had an overall response rate of 32.9% (26/79 evaluable pts). B Introduction: b Previous reviews of phase 1 trials in oncology have reported a treatment response rate of 4%-6% and a toxicity-related mortality rate of 0.5%. All patients were assessed for toxicity and 382/447 (85%) for treatment response. [Extracted from the article]